MGTX - MeiraGTx: An Exciting Gene Therapy Pick In March 2020
Today, we will see why MeiraGTx (MGTX) is an enticing gene therapy pick in March 2020.
Company overview
MeiraGTx is a vertically-integrated, clinical-stage gene therapy company focused on developing novel and cost-effective treatments for diseases with significant unmet demand. Founded in 2015 and headquartered in New York, the company went public in 2018.
The company's diversified gene therapy pipeline comprises of six ongoing clinical programs across indications of inherited retinal diseases, diseases of salivary glands, and PD (Parkinson's disease). The company has developed next-generation gene therapy which works on riboswitch-based gene regulation. This